No Data
89Bio Inc. Reports Q3 2024 Financial Results
89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests From the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting 2024
Express News | 89Bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests From the Enliven Phase 2B Trial in Mash Patients at Aasld the Liver Meeting® 2024
89bio (ETNB) Receives a Hold From Oppenheimer
Reported Earlier, 89bio Prices Upsized $125M Public Offering Of 11,455,882 Common Stock At $8.50/Share And Pre-Funded Warrants
89bio Drops 2%, Prices $125M Stock Offering